A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)

Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43–9006) in the treatment of relapsed DLBCL. Fourteen patients were enrolled and asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenwald, Daniel R, Li, Hailun, Luger, Selina M, Go, Ronald S, King, David, Patel, Taral, Gascoyne, Randy D, Kolesar, Jill, Kahl, Brad S, Horning, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716977/
https://www.ncbi.nlm.nih.gov/pubmed/23829878
http://dx.doi.org/10.1186/1756-8722-6-46

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716977/
https://www.ncbi.nlm.nih.gov/pubmed/23829878
http://dx.doi.org/10.1186/1756-8722-6-46

Ejemplares similares